Sign up to save your podcasts
Or
Share Artificial sweeteners cognition concerns, drug company payments and prescribing decisions, graphene technology
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Artificial sweeteners cognition concerns, drug company payments and prescribing decisions, graphene technology
In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about artificial sweeteners' impact on cognitive health, how drug company payments influence prescribing decisions, and the use of graphene technology to accelerate maturation of neurons.
View all episodes
By American Academy of Neurology
4.7
1919 ratings
In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about artificial sweeteners' impact on cognitive health, how drug company payments influence prescribing decisions, and the use of graphene technology to accelerate maturation of neurons.
More shows like Neurology Today in 5
View all
NEJM This Week
321 Listeners
JAMA Clinical Reviews
501 Listeners
Neurology® Podcast
302 Listeners
Practical Neurology Podcast
49 Listeners
This Week in Cardiology
883 Listeners
JAMA Neurology Author Interviews
12 Listeners
BMJ Best Practice Podcast
21 Listeners
JAMA Medical News
91 Listeners
The Clinical Problem Solvers
517 Listeners
Neurology Minute
133 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
363 Listeners
Neurology Exam Prep Podcast
182 Listeners
The Curious Clinicians
373 Listeners
The Lancet Neurology in conversation with
6 Listeners
Continuum Audio
80 Listeners